



(12) Translation of
European patent specification

(11) NO/EP 2578585 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 473/34 (2006.01)
A61K 31/522 (2006.01)
A61P 7/02 (2006.01)
A61P 29/00 (2006.01)
A61P 35/00 (2006.01)
A61P 37/06 (2006.01)
A61P 43/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.11.21
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.07.20
(86)	European Application Nr.	11789754.6
(86)	European Filing Date	2011.05.30
(87)	The European Application's Publication Date	2013.04.10
(30)	Priority	2010.05.31, JP, 2010123727
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	ONO Pharmaceutical Co., Ltd., 1-5, Doshomachi 2-chome Chuo-ku, Osaka-shi, Osaka 541-8526, JP-Japan
(72)	Inventor	YAMAMOTO, Shingo, c/o ONO PHARMACEUTICAL CO. LTD.1-1 Sakurai 3- chomeShimamoto-cho, Mishima-gunOsaka 618-8585, JP-Japan YOSHIZAWA, Toshio, c/o ONO PHARMACEUTICAL CO. LTD.1-1 Sakurai 3- chomeShimamoto-cho, Mishima-gunOsaka 618-8585, JP-Japan
(74)	Agent or Attorney	Tandbergs Patentkontor AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	PURINONE DERIVATIVE AS BTK KINASE INHIBITOR
(56)	References Cited:	WO-A2-01/19828 WO-A2-03/037890 WO-A2-2005/011597 WO-A2-2008/121742 JP-A- 2003 509 427 JP-A- 2010 504 324

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidiny]-7-(4-fenoksyfenyl)-7,9-dihydro-
5 8H-purin-8-on, eller et salt derav.
2. Forbindelse ifølge krav 1, for fremstilling av 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidiny]-7-(4-fenoksyfenyl)-7,9-dihydro-8H-purin-8-en.